Growing prevalence of chronic kidney disease coupled with an extensive research conducted regarding its medication is the factor majorly augmenting the chronic kidney disease treatment market. Early detection is necessary to avail proper medication.
Therefore, various awareness campaigns are being conducted by the government and non-government agencies worldwide. These campaigns are bound to bring more patients voluntarily to the diagnostic centers.
The chronic kidney disease market manufacturers are working toward devising oral treatments for chronic kidney disease as a form of a painless mode of curing it. They are also looking forward for speedy approvals from the regulatory bodies to have their other therapeutics applicable with less downtime.
Chronic Kidney Disease (CKD) means abnormality of kidneys that does not cure completely. CKD could be detected through urine tests for protein or blood, a blood test for measuring kidney function, or scanning of the kidneys.
A test called estimated glomerular filtration rate (eGFR) is used for measuring kidney function. It is calculated by checking the level of creatinine in blood.
There are two ways to treat CKD; medicine and dialysis. In the latter one, replication of certain functions of the kidney is carried out, which could be essential in the advanced stage (stage 5) of CKD. Medicines help in controlling associated ailments such as high cholesterol and high blood pressure.
However, earlier diagnosis of chronic kidney disease is recommended in order to slow down the progressions of the disease.
| Attribute | Detail |
|---|---|
| Chronic Kidney Disease Treatment Market Drivers |
|
Increasing incidence of chronic diseases throughout the global population is amongst the key factors propagating the chronic kidney disease treatment market. As per the American Kidney Fund’s report published in February 2022, around 37 million Americans are suffering from kidney disease with 92,000 Americans featuring in kidney transplant waiting list.
Moreover, as per statistics published by the American Cancer Society in 2022, close to 79,000 novel cases of kidney cancer were recorded in the U.S. in 2022.
As per the National Kidney Foundation, 10% of the global population worldwide is adversely affected by CKD, and millions succumb to CKD due to lack of affordable courses of treatment.
Need to combat chronic kidney diseases on continuous basis is thus expanding chronic kidney disease treatment market size.
Increase in R&D activities coupled with new product launches are contributing toward boost in revenue. For instance, in March 2022, Lupin introduced Sevelamer Hydrochloride tablets for treating hyperphosphatemia in the patients suffering from CKD in the U.S.
In March 2022, DCGI inked a NDA with Zydus Lifesciences for Oxemia, the first oral treatment in India for anemia linked with chronic kidney disease (CKD).
In March 2022, Nova Biomedical came up with a tool called Nova Max Pro Creatinine/eGFR Meter System in order to enhance kidney care via kidney function screening along with early detection of kidney diseases in point-of-care (POC) settings.
In February 2021, the National Kidney Foundation (NKF) tabled the National Patient Network, the world’s first national registry for the patients at every stage of kidney disease.
In July 2023, the National Institutes of Health (NIH) provided funds for a collaborative project amongst the University of California (UC) Sandiego, Washington University, and various other institutions in order to develop an atlas tool for facilitating treatment related to kidney damage by studying nuclei and cells.
In July 2023, the European Commission (EC) authorized jardiance (empagliflozin) manufactured by Boehringer Ingelheim and Eli Lilly to treat adults with CKD.
Continual R&D activities regarding various CKD therapy options are thus accelerating the chronic kidney disease treatment market development.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the chronic kidney disease treatment market analysis, North America held the largest share in renal disease management landscape in 2023 and the scenario is expected to remain unchanged during the forecast period.
This is attributed to the U.S. being home to well-established healthcare infrastructure due to technologically advanced diagnostics tests and higher healthcare spending by government and non-government agencies. As per the American Kidney Fund, there were close to 135,000 Americans who were newly diagnosed with kidney failure in 2021.
Asia Pacific’s significant chronic kidney disease treatment industry growth is due to increasing awareness regarding symptoms of chronic kidney diseases and their treatment by the governments of the countries such as India and China.
As per the CDC, growing population of elderly people is likely to result in rise in demand for chronic kidney disease treatment in this region. According to Kidney International Reports, 434.3 million individuals in Asia Pacific suffer from chronic kidney diseases (CKDs).
The key participants in advanced kidney disease care landscape are launching new products followed by speedy approvals from regulatory bodies in order to strengthen their position.
In May 2021, the U.S. FDA completed approval of AstraZeneca’s Farxiga for treating chronic kidney disease (CKD) in those with as well as without type-2 diabetes who are at the brim of progression.
The chronic kidney disease treatment market report highlights Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi S.A., GSK plc, Kissei Pharmaceutical, AbbVie Inc., Akebia Therapeutics, Inc., AstraZeneca, Amgen Inc., and Baxter.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 14.3 Bn |
| Market Forecast (Value) in 2034 | US$ 23.3 Bn |
| Growth Rate (CAGR) | 4.7% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 14.3 Bn in 2023
It is projected to grow at a CAGR of 4.7% from 2024 to 2034
Growing prevalence of chronic kidney diseases and noticeable R&D activities
Hospitals & clinics segment accounted for the largest share in 2023
North America was the dominant region in 2023
Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi S.A., GSK plc, Kissei Pharmaceutical, AbbVie Inc., Akebia Therapeutics, Inc., AstraZeneca, Amgen Inc., and Baxter
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Chronic Kidney Disease Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Chronic Kidney Disease Treatment Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Chronic Kidney Disease Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2017-2031
6.3.1. Drug Type
6.3.1.1. ACE Inhibitors
6.3.1.2. Angiotensin-II Receptor Blockers
6.3.1.3. Calcium Channel Blockers
6.3.1.4. Beta Blockers
6.3.1.5. Erythropoiesis-Stimulating Agents (ESAs)
6.3.1.6. Diuretics
6.3.1.7. Others (Phosphate Binders, etc.)
6.3.2. Dialysis
6.3.2.1. Equipment
6.3.2.2. Consumables
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Chronic Kidney Disease Treatment Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2017-2031
7.3.1. Hospitals & Clinics
7.3.2. Dialysis Centers
7.3.3. Others (Research Institutes, etc.)
7.4. Market Attractiveness Analysis, by End-user
8. Global Chronic Kidney Disease Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017-2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Chronic Kidney Disease Treatment Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Treatment Type, 2017-2031
9.3.1. Drug Type
9.3.1.1. ACE Inhibitors
9.3.1.2. Angiotensin-II Receptor Blockers
9.3.1.3. Calcium Channel Blockers
9.3.1.4. Beta Blockers
9.3.1.5. Erythropoiesis-Stimulating Agents (ESAs)
9.3.1.6. Diuretics
9.3.1.7. Others (Phosphate Binders, etc.)
9.3.2. Dialysis
9.3.2.1. Equipment
9.3.2.2. Consumables
9.4. Market Value Forecast, by End-user, 2017-2031
9.4.1. Hospitals & Clinics
9.4.2. Dialysis Centers
9.4.3. Others (Research Institutes, etc.)
9.5. Market Value Forecast, by Country, 2017-2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Treatment Type
9.6.2. By End-user
9.6.3. By Country
10. Europe Chronic Kidney Disease Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment Type, 2017-2031
10.3.1. Drug Type
10.3.1.1. ACE Inhibitors
10.3.1.2. Angiotensin-II Receptor Blockers
10.3.1.3. Calcium Channel Blockers
10.3.1.4. Beta Blockers
10.3.1.5. Erythropoiesis-Stimulating Agents (ESAs
10.3.1.6. Diuretics
10.3.1.7. Others (Phosphate Binders, etc.)
10.3.2. Dialysis
10.3.2.1. Equipment
10.3.2.2. Consumables
10.4. Market Value Forecast, by End-user, 2017-2031
10.4.1. Hospitals & Clinics
10.4.2. Dialysis Centers
10.4.3. Others (Research Institutes, etc.)
10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Chronic Kidney Disease Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment Type, 2017-2031
11.3.1. Drug Type
11.3.1.1. ACE Inhibitors
11.3.1.2. Angiotensin-II Receptor Blockers
11.3.1.3. Calcium Channel Blockers
11.3.1.4. Beta Blockers
11.3.1.5. Erythropoiesis-Stimulating Agents (ESAs)
11.3.1.6. Diuretics
11.3.1.7. Others (Phosphate Binders, etc.)
11.3.2. Dialysis
11.3.2.1. Equipment
11.3.2.2. Consumables
11.4. Market Value Forecast, by End-user, 2017-2031
11.4.1. Hospitals & Clinics
11.4.2. Dialysis Centers
11.4.3. Others (Research Institutes, etc.)
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Chronic Kidney Disease Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment Type, 2017-2031
12.3.1. Drug Type
12.3.1.1. ACE Inhibitors
12.3.1.2. Angiotensin-II Receptor Blockers
12.3.1.3. Calcium Channel Blockers
12.3.1.4. Beta Blockers
12.3.1.5. Erythropoiesis-Stimulating Agents (ESAs)
12.3.1.6. Diuretics
12.3.1.7. Others (Phosphate Binders, etc.)
12.3.2. Dialysis
12.3.2.1. Equipment
12.3.2.2. Consumables
12.4. Market Value Forecast, by End-user, 2017-2031
12.4.1. Hospitals & Clinics
12.4.2. Dialysis Centers
12.4.3. Others (Research Institutes, etc.)
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Chronic Kidney Disease Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment Type, 2017-2031
13.3.1. Drug Type
13.3.1.1. ACE Inhibitors
13.3.1.2. Angiotensin-II Receptor Blockers
13.3.1.3. Calcium Channel Blockers
13.3.1.4. Beta Blockers
13.3.1.5. Erythropoiesis-Stimulating Agents (ESAs)
13.3.1.6. Diuretics
13.3.1.7. Others (Phosphate Binders, etc.)
13.3.2. Dialysis
13.3.2.1. Equipment
13.3.2.2. Consumables
13.4. Market Value Forecast, by End-user, 2017-2031
13.4.1. Hospitals & Clinics
13.4.2. Dialysis Centers
13.4.3. Others (Research Institutes, etc.)
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Teva Pharmaceutical Industries Ltd.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Pfizer Inc.
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Sanofi S.A.
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. GSK plc
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Kissei Pharmaceutical
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. AbbVie Inc.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Akebia Therapeutics, Inc.
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. AstraZeneca
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Amgen Inc.
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Baxter
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
List of Tables
Table 01: Global Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 02: Global Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by End-user, 2017-2031
Table 03: Global Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by Region, 2017-2031
Table 04: North America Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by Country, 2017-2031
Table 05: North America Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 06: North America Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by End-user, 2017-2031
Table 07: Europe Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 08: Europe Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 09: Europe Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by End-user, 2017-2031
Table 10: Asia Pacific Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 11: Asia Pacific Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 12: Asia Pacific Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by End-user, 2017-2031
Table 13: Latin America Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Latin America Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 15: Latin America Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by End-user, 2017-2031
Table 16: Middle East & Africa Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Middle East & Africa Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 18: Middle East & Africa Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Chronic Kidney Disease Treatment Market Size (US$ Bn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Chronic Kidney Disease Treatment Market Revenue (US$ Bn), by Treatment Type, 2022
Figure 03: Global Chronic Kidney Disease Treatment Market Value Share, by Treatment Type, 2022
Figure 04: Global Chronic Kidney Disease Treatment Market Revenue (US$ Bn), by End-user, 2022
Figure 05: Global Chronic Kidney Disease Treatment Market Value Share, by End-user, 2022
Figure 06: Global Chronic Kidney Disease Treatment Market Value Share, by Region, 2022
Figure 07: Global Chronic Kidney Disease Treatment Market Value (US$ Bn) Forecast, 2023-2031
Figure 08: Global Chronic Kidney Disease Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 09: Global Chronic Kidney Disease Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 10: Global Chronic Kidney Disease Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 11: Global Chronic Kidney Disease Treatment Market Attractiveness Analysis, by End-user, 2023-2031
Figure 12: Global Chronic Kidney Disease Treatment Market Value Share Analysis, by Region, 2022 and 2031
Figure 13: Global Chronic Kidney Disease Treatment Market Attractiveness Analysis, by Region, 2023-2031
Figure 14: North America Chronic Kidney Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 15: North America Chronic Kidney Disease Treatment Market Attractiveness Analysis, by Country, 2023-2031
Figure 16: North America Chronic Kidney Disease Treatment Market Value Share Analysis, by Country, 2022 and 2031
Figure 17: North America Chronic Kidney Disease Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 18: North America Chronic Kidney Disease Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 19: North America Chronic Kidney Disease Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 20: North America Chronic Kidney Disease Treatment Market Attractiveness Analysis, by End-user, 2023-2031
Figure 21: Europe Chronic Kidney Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 22: Europe Chronic Kidney Disease Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 23: Europe Chronic Kidney Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 24: Europe Chronic Kidney Disease Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 25: Europe Chronic Kidney Disease Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 26: Europe Chronic Kidney Disease Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 27: Europe Chronic Kidney Disease Treatment Market Attractiveness Analysis, by End-user, 2023-2031
Figure 28: Asia Pacific Chronic Kidney Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 29: Asia Pacific Chronic Kidney Disease Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 30: Asia Pacific Chronic Kidney Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 31: Asia Pacific Chronic Kidney Disease Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 32: Asia Pacific Chronic Kidney Disease Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 33: Asia Pacific Chronic Kidney Disease Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 34: Asia Pacific Chronic Kidney Disease Treatment Market Attractiveness Analysis, by End-user, 2023-2031
Figure 35: Latin America Chronic Kidney Disease Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 36: Latin America Chronic Kidney Disease Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 37: Latin America Chronic Kidney Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 38: Latin America Chronic Kidney Disease Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 39: Latin America Chronic Kidney Disease Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 40: Latin America Chronic Kidney Disease Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 41: Latin America Chronic Kidney Disease Treatment Market Attractiveness Analysis, by End-user, 2023-2031
Figure 42: Middle East & Africa Chronic Kidney Disease Treatment Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 43: Middle East & Africa Chronic Kidney Disease Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 44: Middle East & Africa Chronic Kidney Disease Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 45: Middle East & Africa Chronic Kidney Disease Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 46: Middle East & Africa Chronic Kidney Disease Treatment Market Value Share Analysis, by End-user, 2022 and 2031
Figure 47: Middle East & Africa Chronic Kidney Disease Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 48: Middle East & Africa Chronic Kidney Disease Treatment Market Attractiveness Analysis, by End-user, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Chronic Kidney Disease Treatment Market
